Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. CHYM
4. USO
5. AAPL
6. QCOM
7. IRT
8. ASO
9. LAES
10. PHVS

Go back to Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 
(NASDAQ: RVMD) Delayed: 210.10 +2.78 (1.34%)
Previous Close $207.32    52 Week High $ 
Open $206.01    52 Week Low $ 
Day High $213.00    P/E N/A 
Day Low $204.46    EPS $ 
Volume 387,554